Quantcast
Last updated on April 18, 2014 at 0:09 EDT

Latest Fistula Stories

2010-04-09 09:53:38

Gastrointestinal (GI) chronic perforations require closure and control of extraluminal collections and sepsis. Covered self-expandable metal stents or plastic stents are an effective method in more than 80% of cases, but have many drawbacks. Using the newly designed over-the-scope-clip (OTSC) initially intended for hemostasis of gastrointestinal bleeding to close two chronic inveterate external gastric fistulas, a research team from Italy reported the first successful closure of two...

2010-03-24 09:07:58

Long-term complications after procedures to close coronary artery fistulas are particularly prevalent among those whose abnormal connections to the heart result in drainage into the coronary sinus, according to a study published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association. A coronary artery fistula is an abnormal connection between a coronary artery and a chamber of the heart or vessel. The coronary sinus is the end portion of a large vein at the...

2010-03-08 15:07:00

ATLANTA, March 8 /PRNewswire/ -- In honor of the 100th anniversary of International Women's Day, Health & Development International (HDI) announced the results of its Rapid Maternal Mortality and Obstetric Fistula Prevention Project today, in advance of its second hosted global meeting on this topic to be held at The Carter Center in Atlanta on March 9 and 10. This is the world's first pilot project devoted to the rapid prevention of obstetric fistula in women. Obstetric fistula is...

2009-11-23 09:10:00

WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier...

2009-11-11 11:53:00

MADRID, November 11 /PRNewswire/ -- Cellerix, a product-focused biopharmaceutical company which develops innovative medicines based on cell therapy, today announced the successful first closing of its financing round, raising EUR27 million. Participants in this capital increase included current shareholders and a select group of new investors. Cellerix completed another financing round for EUR27.2 million in September 2007. This round was led by the leading life science venture...

2009-09-15 12:31:00

DENVER, Sept. 15 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized in the state of Virginia for reaching the End Stage Renal Disease (ESRD) Network's patient quality improvement goal. DaVita(R) strives to maximize the well-being and health of dialysis patients in Virginia by promoting increased use of fistulas, thereby minimizing the risk of complications. (Logo:...

2009-08-19 14:18:00

DENVER, Aug. 19 /PRNewswire-FirstCall/ -- DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), is leading Colorado in promoting the well-being and health of patients requiring hemodialysis by increasing the use of arterial venous fistulas (AVFs) and decreasing their risks of complications. (Logo: http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO) The Fistula First Breakthrough Initiative - or the National...

2009-08-12 11:31:36

Hormonal changes during pregnancy increase the lithogenicity of bile and impair gallbladder emptying, which create a favorable environment for gallstone formation. Choledocholithiasis and consequent complications such as pancreatitis and cholangitis are potentially fatal diseases for the mother and fetus. During pregnancy, the treatment is usually conservative since surgery is associated with an increased rate of complications such as preterm labor and spontaneous abortion. In...

2009-07-06 07:10:00

ANN ARBOR, Mich., July 6 /PRNewswire-USNewswire/ -- First-time mom Brandi Phare thought she was all alone when she began suffering postpartum ailments. She experienced pain as a result of multiple tears on her body from giving birth, and also faced severe incontinence. Unbeknownst to Phare, she was in the majority. "Easily over half of women who have vaginal birth, at least their first birth, will have some problem in terms of bowel, bladder or sexual dysfunction that can occur," said Dee...

2009-05-28 06:00:00

Proteon also receives orphan drug designation for its lead product candidate, PRT-201 WALTHAM, Mass., May 28 /PRNewswire/ -- Proteon Therapeutics, Inc., announced today that it has completed a second closing of its Series B equity financing, securing an additional $12 million and increasing the total equity capital raised in this round to $50 million. The additional equity investment came primarily from two new investors, Bessemer Venture Partners and Devon Park Bioventures, as well as from...